Aliskiren
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | + | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1020133/Cv/1'> |
Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension.<ref name="a2">[https://web.archive.org/web/20070322214927/http://www.cbc.ca/cp/HealthScout/070306/6030611AU.html "First Hypertension Drug to Inhibit Kidney Enzyme Approved".] CBC. 2007-03-06. Archived from the original on 2007-03-22. Retrieved 2007-03-14.</ref> | Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension.<ref name="a2">[https://web.archive.org/web/20070322214927/http://www.cbc.ca/cp/HealthScout/070306/6030611AU.html "First Hypertension Drug to Inhibit Kidney Enzyme Approved".] CBC. 2007-03-06. Archived from the original on 2007-03-22. Retrieved 2007-03-14.</ref> | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:34, 20 December 2023
| |||||||||||
References
- ↑ "First Hypertension Drug to Inhibit Kidney Enzyme Approved". CBC. 2007-03-06. Archived from the original on 2007-03-22. Retrieved 2007-03-14.
